InSysBio announces the upcoming webinar on the New Data Annotation Service for CYTOCON DB & fIVE DB on May 19, 2026, 16:00 CEST / 10:00 ET (Microsoft Teams).
Stop mining PubMed. Start modeling.
Before the first equation is written, QSP modelers face a data problem. Sourcing reliable baseline concentrations, extracting kinetic parameters from in vitro studies, standardizing units across dozens of papers, deciding which values to trust — this work typically consumes 4–8 weeks per project, delays model development, and inflates costs.
InSysBio has built two purpose-designed databases to address this bottleneck.
CYTOCON DB is a manually curated database of human in vivo cell and cytokine concentrations: 551 disease types, 253 tissues, 813 molecules, 301 cell types, and over 112,000 standardized data points extracted from nearly 3,000 published sources. Content grows by approximately 1,500 values per month.
fIVE DB captures quantitative parameters derived from in vitro and ex vivo experiments on cell processes — secretion, proliferation, cell death, migration, differentiation, and cytokine degradation — with over 43,000 parameters extracted from 2,247 sources, pre-processed into forms directly usable in mathematical models.
For projects requiring data beyond existing database coverage — rare indications, novel targets, or expanded parameter sets — InSysBio's Data Annotation Service delivers custom, expert-curated datasets within 30 days.
This webinar walks through what each database contains, how the data maps to QSP calibration and virtual patient workflows, and when custom annotation fills the gaps.
WHAT YOU'LL LEARN
Speaker: Vladislav Leonov, CYTOCON DB and fIVE DB Manager.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | August 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
1.
05 Aug 2025 14:26
InSysBio to launch Immune Response Template Open for QSP modeling
InSysBio announces Immune Response Template (IRT) which was previously available under a license model now is completely free to use. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system.
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
1.
19 Aug 2025 15:27
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
The new article “Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology” by Igor Goryanin, Irina Goryanin, Oleg Demin was published in Drug Discovery Today on August 6, 2025
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|